

Shelby Sullivan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1700999/publications.pdf>

Version: 2024-02-01

37
papers

2,560
citations

394421

19
h-index

395702

33
g-index

39
all docs

39
docs citations

39
times ranked

2705
citing authors

#	ARTICLE	IF	CITATIONS
1	Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 68, 1063-1075.	3.7	617
2	ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 425-438.e5.	1.0	347
3	Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 1738-1745.	7.3	245
4	The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. <i>Surgery for Obesity and Related Diseases</i> , 2015, 11, 874-881.	1.2	217
5	Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2017, 112, 447-457.	0.4	146
6	Aspiration Therapy Leads to Weight Loss in Obese Subjects: A Pilot Study. <i>Gastroenterology</i> , 2013, 145, 1245-1252.e5.	1.3	145
7	Endoscopic Bariatric and Metabolic Therapies: New and Emerging Technologies. <i>Gastroenterology</i> , 2017, 152, 1791-1801.	1.3	134
8	Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial. <i>Obesity</i> , 2017, 25, 294-301.	3.0	130
9	ASGE position statement on endoscopic bariatric therapies in clinical practice. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 767-772.	1.0	79
10	Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 1876-1889.	1.2	76
11	Implications of diet on nonalcoholic fatty liver disease. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 160-164.	2.3	53
12	Artificial intelligence in gastrointestinal endoscopy. <i>VideoGIE</i> , 2020, 5, 598-613.	0.7	49
13	Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 1348-1354.	1.2	40
14	Lean NAFLD: an underrecognized and challenging disorder in medicine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 351-366.	5.7	40
15	Real-World Safety and Efficacy of Fluid-Filled Dual Intragastric Balloon for Weight Loss. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1081-1088.e1.	4.4	38
16	812d The Obalon Swallowable 6-Month Balloon System is More Effective Than Moderate Intensity Lifestyle Therapy Alone: Results From a 6-Month Randomized Sham Controlled Trial. <i>Gastroenterology</i> , 2016, 150, S1267.	1.3	36
17	Clinical safety and effectiveness of a swallowable gas-filled intragastric balloon system for weight loss: consecutively treated patients in the initial year of U.S. commercialization. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 417-423.	1.2	30
18	The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 311-316.	2.4	28

#	ARTICLE	IF	CITATIONS
19	Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people. <i>Translational Research</i> , 2011, 158, 302-306.	5.0	20
20	Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes. <i>Diabetes Spectrum</i> , 2017, 30, 258-264.	1.0	15
21	Effect of Short-Term Pritikin Diet Therapy on the Metabolic Syndrome. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 308-312.	1.7	14
22	Aspiration Therapy for Obesity. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2017, 27, 277-288.	1.4	14
23	Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for aspiration therapy. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 334-342.e1.	1.0	12
24	Endoscopic Management. <i>Gastroenterology Clinics of North America</i> , 2016, 45, 673-688.	2.2	8
25	Enhanced EUS imaging (with videos). <i>Gastrointestinal Endoscopy</i> , 2021, 93, 323-333.	1.0	7
26	Effect of Weight Gain and Weight Loss on In Vivo Colonocyte Proliferation Rate in People with Obesity. <i>Obesity</i> , 2017, 25, S81-S86.	3.0	5
27	Clinical workup of fatty liver for the primary care provider. <i>Postgraduate Medicine</i> , 2019, 131, 19-30.	2.0	4
28	Early Experience With Endoscopic Sleeve Gastroplasty and Hints at Mechanisms of Action. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 44-45.	4.4	3
29	A 6-Month Swallowable Balloon System Results In Sustainable Weight Loss At 1 Year: Results from A Prospective, Randomized Sham-Controlled Trial. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, S26-S27.	1.2	2
30	Endoscopic Bariatric Therapy: A Guide to the Intra-gastric Balloon. <i>American Journal of Gastroenterology</i> , 2020, 115, 629-629.	0.4	2
31	Comparison of the Efficacy and Safety of the FDA-approved Intra-gastric Balloon Systems in a Clinical Setting. <i>Journal of Clinical Gastroenterology</i> , 2023, 57, 578-585.	2.2	2
32	Endoscopy in the Management of Obesity. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2013, 23, 165-175.	1.4	1
33	An Unusual Foreign Body Ingestion: To Scope or Not to Scope. <i>Gastroenterology</i> , 2015, 149, e3-e4.	1.3	1
34	Incremental Cost-Effectiveness of Aspiration Therapy vs Bariatric Surgery and No Treatment for Morbid Obesity. <i>American Journal of Gastroenterology</i> , 2020, 115, 481-482.	0.4	0
35	Intra-gastric Balloons and Aspiration Therapy. , 2020, , 181-191.		0
36	Goals of therapy and concurrent lifestyle interventions to compliment endoscopic bariatric and metabolic interventions. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2020, 22, 126-129.	0.9	0

#	ARTICLE	IF	CITATIONS
37	Correspondence on Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2022, , .	1.3	0